Combined treatment of neurovegetative disorders in patients with ischemic heart disease with Long COVID-19 syndrome

Authors

DOI:

https://doi.org/10.14739/mmt.2026.2.342420

Keywords:

coronary artery disease, neurovegetative disorders, treatment, L-arginine, phenibut

Abstract

The aim of the study. To assess the dynamics of neurovegetative disorders in patients with coronary artery disease (CAD) with Long COVID-19 syndrome under the influence of combined treatment with the inclusion of exogenous L-arginine and phenibut in basic therapy.

Materials and methods. A prospective study with parallel distribution and elements of randomization included 31 patients with CAD: stable angina of exertion of functional class II–III (age 69.0 (64.0; 76.0) years)), who had suffered from moderate or severe COVID-19 coronavirus disease with manifestations of Long COVID-19 syndrome. Patients were divided into two groups depending on the prescribed treatment: group I (n = 15) – basic therapy for CAD was used; in group II (n = 16) a combination of L-arginine and phenibut was additionally prescribed against the background of basic therapy. Heart rate variability (HRV) parameters were assessed using 24-hour Holter ECG monitoring, degree of cognitive impairment – MoCa scale, anxiety-depressive – HADS scale, as well as their dynamics under the influence of the treatment.

Results. The use of combination therapy with the inclusion of exogenous L-arginine and phenibut in patients of group II contributed to an increase in the average integral indicator of cognitive status by 9.47 %, as well as a significant decrease in the level of anxiety-depressive symptoms: in the “Anxiety” subscale by 35.97 %, in the “Depression” subscale – by 20.81 % (p < 0.05). In the group receiving combination therapy with exogenous L-arginine and phenibut, a significant positive dynamics of most indicators of total HRV was determined: an increase in SDNNi by 1.22 times and 1.42 times, rMSSD, % by 1.56 times and 1.66 times, HRVT by 1.46 times and 1.40 in the daytime and nighttime periods, respectively. Analysis of HRV spectral indicators showed restoration of sympatho-parasympathetic balance and a significant decrease in the stress index by 1.89 and 2.03 times in the active and passive periods.

Conclusions. Adding exogenous L-arginine and phenibut to the basic therapy in patients with CAD who have had COVID-19 contributes to a significant reduction in anxiety and depressive symptoms, improvement of cognitive function, and stabilization of autonomic regulation of cardiac activity, which indicates a positive neuromodulatory effect of the combination therapy.

Author Biographies

N. S. Mykhailovska, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, DSc, Professor, Head of the Department of General Practice – Family Medicine and Internal Medicine

S. M. Manuilov, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, Assistant at the Department of General Practice – Family Medicine and Internal Medicine

O. O. Lisova, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, Associate Professor of the Department of General Practice – Family Medicine and Internal Medicine

O. V. Shershnyova, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, Associate Professor of the Department of General Practice – Family Medicine and Internal Medicine

H. V. Hrytsai, Zaporizhzhia State Medical and Pharmaceutical University

MD, PhD, Associate Professor of the Department of General Practice – Family Medicine and Internal Medicine

References

  1. Navarese EP, Grzelakowska K, Mangini F, Kubica J, Banach M, Benn M, et al. The spoils of war and the long-term spoiling of health conditions of entire nations. Atherosclerosis. 2022;352:76-9. doi: https://doi.org/10.1016/j.atherosclerosis.2022.05.012
    | |
  2. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2023;613(7942):130-7. doi: https://doi.org/10.1038/s41586-022-05522-2
    | |
  3. Valencise FE, Boschiero MN, Palamim C, Marson F. The COVID-19 impact on the scientific production on the 25 main death causes according to world region. Pulmonology. 2022;28(1):1-3. doi: https://doi.org/10.1016/j.pulmoe.2021.05.011
    | |
  4. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2100-32. doi: https://doi.org/10.1016/S0140-6736(24)00367-2. Erratum in: Lancet. 2024;403(10440):1988. doi: https://doi.org/10.1016/S0140-6736(24)00824-9
    | |
  5. Knapp S, Austin DS, Aita SL, Caron JE, Owen T, Borgogna NC, et al. Neurocognitive and psychiatric outcomes associated with postacute COVID-19 infection without severe medical complication: a meta-analysis. J Neurol Neurosurg Psychiatry. 2024;95(12):1207-16. doi: https://doi.org/10.1136/jnnp-2024-333950
    | |
  6. Vanderheiden A, Klein RS. Neuroinflammation and COVID-19. Curr Opin Neurobiol. 2022;76:102608. doi: https://doi.org/10.1016/j.conb.2022.102608
    | |
  7. Sousa Rêgo LO, Alves Braga LL, Vilas-Boas GS, Oliveira Cardoso MS, Duraes AR. Cardiovascular and Neurological Complications of COVID-19: A Narrative Review. J Clin Med. 2023;12(8):2819. doi: https://doi.org/10.3390/jcm12082819
    | |
  8. Lakhan R, Agrawal A, Sharma M. Prevalence of Depression, Anxiety, and Stress during COVID-19 Pandemic. J Neurosci Rural Pract. 2020;11(4):519-25. doi: https://doi.org/10.1055/s-0040-1716442
    | |
  9. Mader MM, Czorlich P. The role of L-arginine metabolism in neurocritical care patients. Neural Regen Res. 2022;17(7):1446-53. doi: https://doi.org/10.4103/1673-5374.327331
    | |
  10. Penzak SR, Bulloch M. Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal. J Clin Pharmacol. 2024;64(6):652-71. doi: https://doi.org/10.1002/jcph.2414
    | |
  11. Manuilov SM, Mikhailovska NS. [Characteristics of neurovegetative disorders in ischemic heart disease patients after coronavirus disease 2019 (COVID-19)]. Zaporozhye medical journal. 2024;26(2):106-13. Ukrainian. doi: https://doi.org/10.14739/2310-1210.2024.2.297015
    |
  12. Manuilov SM, Mykhailovska NS. [Structural and functional changes of the heart in patients with coronary heart disease who have had coronavirus disease COVID-19]. Modern medical technology. 2024;16(2):86-92. Ukrainian. doi: https://doi.org/10.14739/mmt.2024.2.301678
    |
  13. Liu Q, Li Y, Shi Y, Tan J, Yan W, Zhang J, et al. The protective effect of gamma aminobutyric acid B receptor activation on sympathetic nerve remodeling via the regulation of M2 macrophage polarization after myocardial infarction. Rev Port Cardiol. 2023;42(2):125-35. English, Portuguese. doi: https://doi.org/10.1016/j.repc.2021.10.011
    | |
  14. Kyrychenko O, Grebeniuk D, Ksenchyn O, Hnatyuk Y, Sobko V, Stoika V. Preclinical and clinical safety of phenibute: a literature review. Perspectives and Innovations of Science. 2024;(4). Ukrainian. doi: https://doi.org/10.52058/2786-4952-2024-4(38)-1271-1285
  15. Prévot T, Sibille E. Altered GABA-mediated information processing and cognitive dysfunctions in depression and other brain disorders. Mol Psychiatry. 2021;26(1):151-67. doi: https://doi.org/10.1038/s41380-020-0727-3
    | |
  16. Khaustova OO, Avramenko OM. Stres ta tryvoha: psykhosomatychnyi pidkhid do terapii [Stress and anxiety: a psychosomatic approach to therapy]. Ukrainskyi medychnyi chasopys. 2023;(5):3-6. Ukrainian. doi: https://doi.org/10.32471/umj.1680-3051.157.248382
  17. Kupats E, Vrublevska J, Zvejniece B, Vavers E, Stelfa G, Zvejniece L, et al. Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports. Pharmacopsychiatry. 2020;53(5):201-8. doi: https://doi.org/10.1055/a-1151-5017
    | |
  18. Mone P, Pansini A, Jankauskas SS, Varzideh F, Kansakar U, Lombardi A, et al. L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults. Front Cardiovasc Med. 2022;9:868521. doi: https://doi.org/10.3389/fcvm.2022.868521
    | |
  19. Salmani M, Alipoor E, Navid H, Farahbakhsh P, Yaseri M, Imani H. Effect of l-arginine on cardiac reverse remodeling and quality of life in patients with heart failure. Clin Nutr. 2021;40(5):3037-44. doi: https://doi.org/10.1016/j.clnu.2021.01.044
    | |
  20. Bangsumruaj J, Kijtawornrat A, Kalandakanond-Thongsong S. Effects of chronic mild stress on GABAergic system in the paraventricular nucleus of hypothalamus associated with cardiac autonomic activity. Behav Brain Res. 2022;432:113985. doi: https://doi.org/10.1016/j.bbr.2022.113985
    | |
  21. Hepsomali P, Groeger JA, Nishihira J, Scholey A. Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review. Front Neurosci. 2020;14:923. doi: https://doi.org/10.3389/fnins.2020.00923
    | |
  22. Abdel-Salam O, Baset M, Omara EA, Sleem AA. Protection by L-arginine against epinephrine-induced arrhythmia and cardiotoxicity. Innov Discov. 2024;1(2):12. doi: https://doi.org/10.53964/id.2024012
  23. Porto AA, Gonzaga LA, Gomes RL, Candeloro BM, Raimundo RD, Vanderlei L, et al. VE. Acute effects of l-arginine intake on heart rate variability after a submaximal exercise test in healthy men: randomized clinical trial. Nitric Oxide. 2025;157:68-73. doi: https://doi.org/10.1016/j.niox.2025.05.003
    | |

Downloads

Additional Files

Published

2026-06-09

How to Cite

Mykhailovska, N. S., Manuilov, S. M., Lisova, O. O., Shershnyova, O. V., & Hrytsai, H. V. (2026). Combined treatment of neurovegetative disorders in patients with ischemic heart disease with Long COVID-19 syndrome. Modern Medical Technology, 18(2), 97–104. https://doi.org/10.14739/mmt.2026.2.342420

Issue

Vol. 18 No. 2 (2026)

Section

Original research

License

Copyright (c) 2026 N. S. Mykhailovska, S. M. Manuilov, O. O. Lisova, O. V. Shershnyova, H. V. Hrytsai

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The work is provided under the terms of the Public Offer and of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows an unlimited number of persons to reproduce and share the Licensed Material in all media and formats. Any use of the Licensed Material shall contain an identification of its Creator(s) and must be for non-commercial purposes only.